The article titled, “Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs,” which was published in the June 2012 issue of Molecular Cancer Therapeutics (1), is being retracted at the request of the University of California, Los Angeles (UCLA) and the author.

The AACR Publications Department received a letter from the Research Integrity Officer for UCLA notifying the Journal that an internal investigation revealed data used in some of the figures cannot be supported; specifically, bands in lanes 2 and 3 in the β-actin panel in Fig. 3C are duplicates of bands in lanes 1 and 2 in the M202R1 HMG-1 panel in Fig. 4C in a 2011 Cancer Research article (2). In addition, bands in lanes 4 and 5 in the β-actin panel in Fig. 3C are duplicates of bands in lanes 4 and 5 of the M329R1 HMG-1 panel in Fig. 4C in the same Cancer Research article. The AACR Publications Department also received a separate retraction request from the author (J.S. Economou). Both authors have been notified of this retraction.

1.
Jazirehi
AR
,
Economou
JS
. 
Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs
.
Mol Cancer Ther
2012
;
11
:
1332
41
.
2.
Jazirehi
AR
,
Baritaki
S
,
Koya
RC
,
Bonavida
B
,
Economou
JS
. 
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction
.
Cancer Res
2011
;
71
:
1406
17
.